{"product_id":"understanding-liver-cancer-where-it-starts-how-its-classified-and-what-this-means-for-patients","title":"Understanding Liver Cancer: Where It Starts, How It's Classified, and What This Means for Patients","description":"\u003cp\u003ePrimary liver cancer, the second leading cause of cancer-related death worldwide, is actually a family of different diseases with distinct molecular fingerprints and origins. Researchers now believe that most liver cancers arise from adult hepatocytes—the liver's main workhorse cells—which can transform directly into cancer cells, or even rewind their developmental clock to become more primitive cells that then give rise to tumors. Scientists have identified specific molecular subtypes of liver cancer that behave differently and carry different prognoses, and they have pinpointed genetic changes—such as mutations in isocitrate dehydrogenase genes (found in roughly 60% of intrahepatic cholangiocarcinomas) and amplifications at chromosomes 11q13 and 6p21 (found in about 30% of hepatocellular carcinomas)—that may one day guide personalized treatment decisions.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Liver Cancer: Where It Starts, How It's Classified, and What This Means for Patients\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eIntroduction: A Growing Global Health Crisis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#liver-structure\"\u003eThe Liver's Building Blocks: Understanding the Basics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#origin-debate\"\u003eThe Big Question: Where Does Liver Cancer Begin?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#regeneration\"\u003eProgenitor Cells and Liver Regeneration\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#progenitor-precursors\"\u003eCan Progenitor Cells Give Rise to Cancer?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#hepatocyte-origin\"\u003eAdult Hepatocytes: The Primary Source of Liver Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#immune-response\"\u003eThe Immune System's Role in Liver Cancer Development\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#molecular-classification\"\u003eMolecular Classification: Profiling Liver Tumors by Their Genes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment-targets\"\u003eGenetic Alterations and Potential Treatment Targets\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#prognosis\"\u003eWhat This Means for Patient Prognosis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: From Laboratory to Bedside\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What Research Cannot Yet Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Researchers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePrimary liver cancer is a family of diseases, with hepatocellular carcinoma accounting for about 90% of cases.\u003c\/li\u003e\n\u003cli\u003eMost liver cancers arise from adult hepatocytes, which can transform directly or rewind into more primitive cells.\u003c\/li\u003e\n\u003cli\u003eLiver cancers are classified into molecular subtypes, with proliferation subtypes linked to more aggressive disease.\u003c\/li\u003e\n\u003cli\u003eTargetable genetic changes include FGFR2 fusions and IDH mutations in iCCA, and 11q13\/6p21 amplifications in HCC.\u003c\/li\u003e\n\u003cli\u003eChronic inflammation is present in 90% of liver tumors, highlighting the importance of treating underlying liver disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eIntroduction: A Growing Global Health Crisis\u003c\/h2\u003e\n\u003cp\u003eLiver cancer is currently the \u003cstrong\u003esecond most common cause of cancer-related death worldwide\u003c\/strong\u003e, making it a major public health challenge that demands urgent attention. Unlike many other types of cancer that have seen declining death rates in recent decades, liver cancer is one of the few malignancies whose incidence and mortality have been steadily increasing. In fact, the \u003cstrong\u003eUnited States has experienced the highest increase in liver cancer mortality of any country during the last two decades\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eLiver cancer is not a single disease but rather a \u003cstrong\u003eheterogeneous group of malignant tumors\u003c\/strong\u003e with different microscopic features and generally unfavorable prognoses. This family of diseases includes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHepatocellular carcinoma (HCC)\u003c\/strong\u003e — the most common form, accounting for about 90% of all primary liver cancer cases\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntrahepatic cholangiocarcinoma (iCCA)\u003c\/strong\u003e — cancer of the bile ducts within the liver\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMixed hepatocellular-cholangiocarcinoma (HCC-CCA)\u003c\/strong\u003e — tumors with features of both HCC and iCCA\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFibrolamellar carcinoma\u003c\/strong\u003e — a rare variant of HCC\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHepatoblastoma\u003c\/strong\u003e — a pediatric liver tumor\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOf these, HCC and iCCA are by far the most common, while the other tumor types—including mixed HCC-CCA tumors—account for \u003cstrong\u003eless than 1% of cases\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe global burden of liver cancer is climbing at an alarming rate. Researchers project that \u003cstrong\u003ethere could be 1 million new cases worldwide by the year 2030\u003c\/strong\u003e. This projection highlights the urgent need for better prevention strategies, earlier detection methods, and more effective treatments.\u003c\/p\u003e\n\n\u003ch3\u003eA Closer Look at HCC: The Dominant Form of Liver Cancer\u003c\/h3\u003e\n\u003cp\u003eHepatocellular carcinoma alone accounts for \u003cstrong\u003e90% of all primary liver cancer cases\u003c\/strong\u003e, with nearly \u003cstrong\u003e800,000 new cases diagnosed each year\u003c\/strong\u003e. The highest incidence rates are found in \u003cstrong\u003eAsia and Sub-Saharan Africa\u003c\/strong\u003e, driven largely by the high prevalence of hepatitis B virus (HBV) infection in these regions.\u003c\/p\u003e\n\n\u003cp\u003eUnlike many other cancers where risk factors remain poorly understood, the main risk factors for HCC are well defined:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eViral hepatitis\u003c\/strong\u003e — chronic infection with hepatitis B virus (HBV) and\/or hepatitis C virus (HCV)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlcohol abuse\u003c\/strong\u003e — heavy, prolonged alcohol consumption damages liver tissue\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-alcoholic fatty liver disease (NAFLD)\u003c\/strong\u003e — fat accumulation in the liver, often associated with metabolic syndrome and diabetes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAdditional co-factors can amplify the risk of developing HCC. \u003cstrong\u003eAflatoxin B1\u003c\/strong\u003e, a toxin produced by certain molds that contaminate food supplies, and \u003cstrong\u003etobacco use\u003c\/strong\u003e both increase the incidence of the disease—but particularly when other common risk factors are already present. This interaction between risk factors underscores the importance of comprehensive prevention approaches.\u003c\/p\u003e\n\n\u003ch3\u003eIntrahepatic Cholangiocarcinoma: The Second Most Common Liver Cancer\u003c\/h3\u003e\n\u003cp\u003eiCCA is the second most common primary liver cancer, but its geographic distribution differs dramatically from HCC. The highest incidence is found in \u003cstrong\u003eSoutheast Asia, where rates reach 30–40 cases per 100,000 inhabitants\u003c\/strong\u003e, while Western countries have much lower rates at \u003cstrong\u003efewer than 5 cases per 100,000 inhabitants\u003c\/strong\u003e. Nevertheless, incidence rates have been steadily increasing in all regions, a trend that mirrors the overall rise in liver cancer burden.\u003c\/p\u003e\n\n\u003cp\u003eRisk factors specific to iCCA include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrimary sclerosing cholangitis (PSC)\u003c\/strong\u003e — a chronic inflammatory disease of the bile ducts\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiliary duct cysts\u003c\/strong\u003e — congenital abnormalities of the bile ducts\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHepatolithiasis\u003c\/strong\u003e — stones within the bile ducts of the liver\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParasitic biliary infestation with flukes\u003c\/strong\u003e — an etiology prevalent in Asia and linked to a specific molecular fingerprint in the tumors\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMore recently, researchers have identified \u003cstrong\u003eshared risk factors with HCC\u003c\/strong\u003e, including chronic HBV and HCV infection—particularly for iCCAs that develop in an already cirrhotic (scarred) liver. This overlap in risk factors hints at deeper biological connections between these two cancer types.\u003c\/p\u003e\n\n\u003cp\u003eHistorically, HCC and iCCA were considered completely independent tumors originating from entirely different cell populations. However, recent research has begun to reframe them as \u003cstrong\u003esubtypes along a continuous spectrum of liver diseases\u003c\/strong\u003e. This evolving understanding has profound implications for how we think about cancer development, classification, and treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"liver-structure\"\u003eThe Liver's Building Blocks: Understanding the Basics\u003c\/h2\u003e\n\u003cp\u003eTo understand where liver cancer begins, we first need to appreciate the liver's normal architecture. The liver is composed of two main categories of cells:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eParenchymal cells\u003c\/strong\u003e — the functional cells of the liver — include \u003cstrong\u003ehepatocytes\u003c\/strong\u003e (the liver's primary metabolic cells) and \u003cstrong\u003echolangiocytes\u003c\/strong\u003e (cells that line the bile ducts). \u003cstrong\u003eNon-parenchymal cells\u003c\/strong\u003e provide structural and supportive functions and include fibroblasts, stellate cells, Kupffer cells (the liver's resident immune cells), and endothelial cells (which line blood vessels).\u003c\/p\u003e\n\n\u003cp\u003eHepatocytes are the liver's heavy lifters, constituting \u003cstrong\u003e60% to 80% of the total liver mass\u003c\/strong\u003e. These cells are organized into functional units called \u003cstrong\u003elobules\u003c\/strong\u003e, which can be further divided into distinct functional regions or zones. This structural organization, known as \u003cstrong\u003eliver zonation\u003c\/strong\u003e, is particularly important because it affects hepatocyte function without altering their basic identity.\u003c\/p\u003e\n\n\u003cp\u003eOne remarkable feature of hepatocytes is their tendency to become \u003cstrong\u003epolyploid\u003c\/strong\u003e—meaning they contain multiple copies of the genetic material. A normal human cell is diploid (2N), containing two sets of chromosomes. Hepatocytes frequently become tetraploid (4N), octoploid (8N), or even higher. These polyploid cells make up an astonishing \u003cstrong\u003e50% of the human liver and 90% of the mouse liver\u003c\/strong\u003e. The significance of polyploidy in cancer development is an area of active investigation.\u003c\/p\u003e\n\n\u003ch2 id=\"origin-debate\"\u003eThe Big Question: Where Does Liver Cancer Begin?\u003c\/h2\u003e\n\u003cp\u003eLiver tumors are notoriously heterogeneous—they look different not only between different patients but even within the same tumor. Some subtypes of HCCs and iCCAs display features that resemble \u003cstrong\u003estem cells\u003c\/strong\u003e (the body's master cells capable of developing into many cell types). For example, HCCs that contain cells positive for the marker \u003cstrong\u003eCK19\u003c\/strong\u003e show stem cell characteristics. Additionally, the rare mixed HCC-CCA tumors contain cells with a phenotype intermediate between hepatocytes and cholangiocytes, as if the cancer cells are caught between two identities.\u003c\/p\u003e\n\n\u003cp\u003eThese observations have sparked one of the most fundamental debates in liver cancer research: \u003cstrong\u003ewhich cell type actually gives rise to the tumor?\u003c\/strong\u003e Two main hypotheses have emerged:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHypothesis 1: The progenitor cell theory.\u003c\/strong\u003e Hepatic progenitor cells—primitive cells that can develop into either hepatocytes or cholangiocytes—might be the source of primary liver tumors. During liver development, both hepatocytes and cholangiocytes arise from a common progenitor called \u003cstrong\u003ehepatoblasts\u003c\/strong\u003e. If these progenitor cells remain in the adult liver and acquire cancer-causing mutations, they could generate tumors with mixed features.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHypothesis 2: The mature cell theory.\u003c\/strong\u003e HCC and iCCA might be distinct tumors that originate from fully mature, differentiated cells—\u003cstrong\u003ehepatocytes for HCC and cholangiocytes for iCCA\u003c\/strong\u003e—which then undergo malignant transformation.\u003c\/p\u003e\n\n\u003cp\u003eThe reality, as this review reveals, is more complex than either hypothesis alone. Recent studies indicate that \u003cstrong\u003eadult hepatocytes can be the source of HCCs through multiple mechanisms\u003c\/strong\u003e:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDirect transformation:\u003c\/strong\u003e Hepatocytes degenerate directly into HCC cells following a sequence of genetic insults.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDe-differentiation:\u003c\/strong\u003e Hepatocytes rewind their developmental state to become precursor cells, which then transform into HCC cells that express progenitor cell markers.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrans-differentiation:\u003c\/strong\u003e Hepatocytes convert into biliary-like cells (resembling bile duct cells), which can then transform into iCCA.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIn parallel, \u003cstrong\u003eprogenitor cells may also give rise to HCCs and iCCAs\u003c\/strong\u003e that display progenitor-like features. Meanwhile, adult cholangiocytes, which lack the plasticity and transforming capacity of hepatocytes, appear to only give rise to iCCAs, not HCCs.\u003c\/p\u003e\n\n\u003ch2 id=\"regeneration\"\u003eProgenitor Cells and Liver Regeneration\u003c\/h2\u003e\n\u003cp\u003eAdult stem cells, also called \u003cstrong\u003esomatic stem cells\u003c\/strong\u003e, are defined as undifferentiated cells with essentially limitless replicative potential. They can differentiate into all or some specialized cell types, and their primary role is to sustain normal tissue turnover and direct tissue repair after injury.\u003c\/p\u003e\n\n\u003cp\u003eStem cell compartments have been successfully identified in several adult tissues with fast turnover rates, including the gastrointestinal tract, skin, and bone marrow. Because of their self-renewal potential and long lifespan, these cells are thought to be \u003cstrong\u003emore prone to malignant transformation\u003c\/strong\u003e—they live long enough to accumulate the multiple genetic mutations needed for cancer to develop. Indeed, stem cells have been identified as the cell of origin for cancers in several organs, including the skin and intestine.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the adult liver presents a different scenario. Liver cells have a \u003cstrong\u003erelatively slow turnover rate\u003c\/strong\u003e, with an average hepatocyte life span ranging from \u003cstrong\u003e200 to 300 days\u003c\/strong\u003e. In this context, the contribution of stem cells to normal liver turnover is not entirely clear and remains an active area of investigation.\u003c\/p\u003e\n\n\u003cp\u003eIn normal conditions, hepatocytes are \u003cstrong\u003equiescent\u003c\/strong\u003e—they sit quietly without dividing. But upon liver injury or after a significant reduction of liver mass (such as following partial hepatectomy for tumor removal or living-donor transplantation), the liver's regenerative machinery kicks into high gear. Adult hepatocytes have an \u003cstrong\u003eenormous proliferative potential, with the capacity to replicate more than 50 times\u003c\/strong\u003e. This remarkable regenerative ability is what makes human liver transplantation from living donors possible as a standard treatment for end-stage liver disease.\u003c\/p\u003e\n\n\u003cp\u003eThere is strong evidence that regeneration after partial hepatectomy relies predominantly on the \u003cstrong\u003ereplication of existing hepatocytes\u003c\/strong\u003e rather than on stem cells. However, when the replicative capacity of hepatocytes is severely impaired—such as in patients with acute liver failure or chronic hepatitis—a different population of cells emerges and expands. These cells, known as \u003cstrong\u003eoval cells\u003c\/strong\u003e, have features intermediate between hepatocytes and cholangiocytes. They are thought to reside in the peri-portal area of the liver lobule, in structures called the \u003cstrong\u003ecanals of Hering\u003c\/strong\u003e, and are considered \u003cstrong\u003ebi-potential progenitors\u003c\/strong\u003e—meaning they can develop into either hepatocytes or bile duct cells.\u003c\/p\u003e\n\n\u003cp\u003eThe regenerative capacity of oval cells has been dramatically demonstrated in mouse studies: in animals with massive liver damage, these cells restored \u003cstrong\u003emore than 80% of hepatocytes\u003c\/strong\u003e. Other studies from liver injury models have supported what is known as the \u003cstrong\u003eliver stem cell hypothesis\u003c\/strong\u003e, showing proliferation of duct-like cells (frequently termed the \"ductular reaction\") in the portal zone of the hepatic lobule. However, this interpretation remains controversial among liver biologists.\u003c\/p\u003e\n\n\u003cp\u003eInterestingly, chronic injury from hepatitis C virus (HCV) can induce \u003cstrong\u003eductular metaplasia and proliferation\u003c\/strong\u003e, with mature hepatocytes trans-differentiating into bi-potential oval cells via a process of \u003cstrong\u003eepigenetic re-programming\u003c\/strong\u003e—essentially, the cells change which genes are turned on or off without altering the underlying DNA sequence. These cells appear distinct from the classical oval cells of the canals of Hering and may play a more relevant role in liver cancer development.\u003c\/p\u003e\n\n\u003cp\u003eBeyond oval cells, researchers have identified several other specialized cell populations with regenerative potential:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeri-central liver cells:\u003c\/strong\u003e Specialized cells located around the central vein, capable of self-renewal in the uninjured liver under the influence of endothelial Wnt signaling. These cells express the early liver progenitor marker TBX3 and are diploid (containing the normal two sets of chromosomes).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHybrid periportal cells:\u003c\/strong\u003e Cells located near the portal tract that express hepatocyte markers along with low levels of SOX9 and several bile duct genes. These cells can repopulate both healthy and diseased liver tissue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIt remains unclear whether these cell populations are \u003cstrong\u003ebona fide stem or progenitor cells\u003c\/strong\u003e, distinct hepatocyte subpopulations, or something in between—and whether they contribute to tumor formation.\u003c\/p\u003e\n\n\u003ch2 id=\"progenitor-precursors\"\u003eCan Progenitor Cells Give Rise to Cancer?\u003c\/h2\u003e\n\u003cp\u003eExtensive experimental evidence supports the hypothesis that progenitor cells can originate liver cancer. Several elegant animal studies have demonstrated this connection:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHippo pathway studies:\u003c\/strong\u003e Mice with genetic alterations affecting the Hippo signaling pathway (a key regulator of organ size and cell growth) within the liver expand progenitor-like cells and subsequently develop HCC, iCCA, and mixed HCC-CCA tumors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNF2 gene studies:\u003c\/strong\u003e Liver-specific deletion of the neurofibromatosis type 2 (NF2) tumor suppressor gene in developing or adult mice leads to expansion of progenitor cells without affecting differentiated hepatocytes. These mice develop both HCC and iCCA.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOncogene activation studies:\u003c\/strong\u003e Almost any mouse hepatic cell—including hepatic progenitors, hepatoblasts, and hepatocytes—that expresses activated oncogenes such as H-RAS or SV40LT can undergo transformation to develop into iCCAs or HCCs. This suggests that the cell of origin may be less important than the specific genetic mutations involved.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeribiliary gland studies:\u003c\/strong\u003e There may be subpopulations of stem or progenitor cells in peribiliary glands (glands located throughout the biliary tree) that give rise to iCCAs or fibrolamellar HCC.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eKey signaling pathways control whether progenitor cells develop toward hepatocyte or cholangiocyte fates:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMET:\u003c\/strong\u003e Primarily induces hepatocyte differentiation\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEGFR (Epidermal Growth Factor Receptor):\u003c\/strong\u003e Promotes cholangiocyte specification\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNotch:\u003c\/strong\u003e Promotes cholangiocyte specification; activation of Notch in mice leads to development of both HCC and iCCA\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eGenetic mutations also play a role in shifting progenitor cell fate. \u003cstrong\u003eMutations in genes encoding isocitrate dehydrogenases (IDH)\u003c\/strong\u003e—which are frequently detected in iCCAs but rarely in HCCs—inhibit hepatocyte differentiation and promote oval cell proliferation and biliary transformation following liver injury, particularly when they cooperate with \u003cstrong\u003eKRAS mutations\u003c\/strong\u003e. Similarly, \u003cstrong\u003eKRAS mutations combined with homozygous PTEN deletion\u003c\/strong\u003e in embryonic bi-potential progenitor cells cooperate to induce the onset of iCCA.\u003c\/p\u003e\n\n\u003cp\u003eOverall, these experimental studies strongly implicate progenitor cells in the development of both of the most common primary liver cancers.\u003c\/p\u003e\n\n\u003ch2 id=\"hepatocyte-origin\"\u003eAdult Hepatocytes: The Primary Source of Liver Cancer\u003c\/h2\u003e\n\u003cp\u003eDespite the evidence supporting progenitor cells as cancer precursors, a growing body of research points to \u003cstrong\u003eadult hepatocytes as the primary cell of origin in liver cancer\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eStudies using advanced \u003cstrong\u003efate-tracing systems\u003c\/strong\u003e—techniques that permanently label specific cells and track their descendants—have observed that HCC does not originate from progenitor cells but rather from \u003cstrong\u003ehepatocytes\u003c\/strong\u003e in both hepatotoxin-induced and carcinogen-free (Mdr2 knock-out) mouse models. Specifically, these data indicate that \u003cstrong\u003eFoxl1-positive cells\u003c\/strong\u003e (which express the progenitor markers EPCAM, SOX9, and PROM1) do not contribute to HCC tumorigenesis, in agreement with other studies showing that biliary cells do not give rise to HCC.\u003c\/p\u003e\n\n\u003cp\u003eFurther supporting the hepatocyte origin theory, a recent study demonstrated that \u003cstrong\u003ehepatocyte-specific expression of p62\u003c\/strong\u003e—a protein involved in cellular stress responses—promotes c-MYC induction, mTORC1 activation, and HCC initiation.\u003c\/p\u003e\n\n\u003cp\u003eAdult hepatocytes possess several properties that make them plausible cancer-initiating cells:\u003c\/p\u003e\n\n\u003ch3\u003eRemarkable Plasticity: De-differentiation\u003c\/h3\u003e\n\u003cp\u003eMature hepatocytes can de-differentiate—essentially revert to a more primitive state—following loss of the tumor suppressor \u003cstrong\u003eTP53\u003c\/strong\u003e. This yields \u003cstrong\u003enestin-positive progenitor-like cells\u003c\/strong\u003e that can expand and generate primary liver cancers after acquiring lineage-specific oncogenic lesions, such as mutations in \u003cstrong\u003eWNT\u003c\/strong\u003e (leading to HCC) or \u003cstrong\u003eNotch\u003c\/strong\u003e (leading to iCCA).\u003c\/p\u003e\n\n\u003ch3\u003eTrans-differentiation into Biliary Cells\u003c\/h3\u003e\n\u003cp\u003eAdult hepatocytes can also trans-differentiate into biliary-like cells that can degenerate into iCCA. Upon liver injury, \u003cstrong\u003eNotch activation leads to reprogramming of mature hepatocytes into cells that closely resemble biliary epithelial cells\u003c\/strong\u003e, ultimately inducing iCCA. Notch can accomplish this transformation on its own or in cooperation with \u003cstrong\u003eAKT\u003c\/strong\u003e, another key signaling molecule.\u003c\/p\u003e\n\n\u003ch3\u003eA Unified Model of Liver Cancer Origins\u003c\/h3\u003e\n\u003cp\u003eThere is now evidence that \u003cstrong\u003edifferent cell types can serve as the cell of origin for primary liver cancers\u003c\/strong\u003e, depending on the specific circumstances. Two complementary features of HCC and iCCA could account for their phenotypic complexity: their molecular features (which pathways are activated, which mutations are present) and the types of cells that become transformed.\u003c\/p\u003e\n\n\u003cp\u003eFor example, development of HCC could involve specific molecular alterations in adult hepatocytes, whereas iCCA could originate from cholangiocytes—probably as a result of chronic biliary damage due to liver flukes, primary sclerosing cholangitis, or other insults. However, the picture is more nuanced:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumors with progenitor cell phenotype\u003c\/strong\u003e could derive from progenitor-like cells, either because they are bona fide progenitor cells or following de-differentiation of adult hepatocytes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransformation of progenitor cells\u003c\/strong\u003e could occur at any stage of hepatic development, giving rise to tumors of different morphologies—ranging from HCC and iCCA with stem-cell phenotypes to mixed HCC-CCAs. Clinical and pathology analyses of mixed HCC-CCAs have indeed indicated an origin from the progenitor cell compartment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMature hepatocytes can trans-differentiate\u003c\/strong\u003e, generally as a result of viral infection, into biliary-like cells that give rise to iCCA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRegardless of their cell of origin—whether mature hepatocytes or progenitor cells—liver cancers with \u003cstrong\u003estem cell features have a more aggressive clinical behavior and worse prognosis\u003c\/strong\u003e than those without these features. This finding has important clinical implications, as identifying stem cell markers could help predict which patients are at higher risk for aggressive disease.\u003c\/p\u003e\n\n\u003cp\u003eHowever, these questions are difficult to study due to discrepancies between mouse models and human disease. Researchers need to determine under what circumstances adult hepatic cells, rather than progenitor cells, give rise to liver tumors and vice versa—and to bridge the gap between findings from animal model studies and observations in patients with severe liver injury. It will also be important to determine the dominant reprogramming events involved in tumorigenesis in different species, and to explore which cells are most affected by oncogene mutations associated with HCC, such as those in the \u003cstrong\u003eTERT promoter\u003c\/strong\u003e or \u003cstrong\u003eCTNNB1\u003c\/strong\u003e genes.\u003c\/p\u003e\n\n\u003ch2 id=\"immune-response\"\u003eThe Immune System's Role in Liver Cancer Development\u003c\/h2\u003e\n\u003cp\u003eRegardless of which cell type becomes transformed to initiate tumorigenesis, the developing tumor also requires a specific microenvironment to thrive. This is particularly relevant to liver tumors, \u003cstrong\u003e90% of which develop under conditions of chronic inflammation\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSeveral factors contribute to tumor formation in the inflamed liver:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChanges in the extracellular matrix\u003c\/strong\u003e — the structural scaffold that supports cells\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eSignaling between parenchymal and non-parenchymal cells\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImmune dysfunction\u003c\/strong\u003e — an altered immune response is now recognized as an important factor in carcinogenesis\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCancer cells produce growth factors and \u003cstrong\u003eangiogenic factors\u003c\/strong\u003e (substances that promote blood vessel formation) that fuel tumor growth, invasion, and metastasis. iCCAs, in particular, typically develop under conditions of chronic inflammation due to viral infections (in \u003cstrong\u003eabout 20% of cases\u003c\/strong\u003e), chronic fluke infestation, primary sclerosing cholangitis, and hepatolithiasis.\u003c\/p\u003e\n\n\u003cp\u003eChronic inflammation contributes to liver carcinogenesis through a vicious \u003cstrong\u003ecycle of cell death and regeneration\u003c\/strong\u003e: damaged cells die, triggering regeneration, which leads to production of cell survival and proliferation signals that promote formation of regenerative nodules, then dysplasia, and ultimately cancer.\u003c\/p\u003e\n\n\u003cp\u003eIn this context, the phenotype of liver tumors could depend on interactions between oncogenes and the immune microenvironment. In a recent animal study, different types of liver tumors—HCCs, iCCAs, and mixed HCC-CCA—arose via activation of distinct oncogenes such as \u003cstrong\u003eAKT1\u003c\/strong\u003e and \u003cstrong\u003eCTNNB1\u003c\/strong\u003e, in combination with inflammatory microenvironment conditions such as treatment with carbon tetrachloride or a special diet (3,5-diethoxycarbonyl-1,4-dihydrocollidine). Remarkably, tumors that develop via activation of the same oncogenes can still have completely different gene expression patterns (transcriptomes), depending on the level of inflammation and features of the microenvironment. This reveals the profound influence of the inflammatory context on tumor behavior.\u003c\/p\u003e\n\n\u003ch3\u003eKey Mechanisms Linking the Immune System to Liver Cancer\u003c\/h3\u003e\n\u003cp\u003eSeveral specific mechanisms connect immune system activity with liver cancer development:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCytokine secretion:\u003c\/strong\u003e Immune cells secrete signaling molecules called cytokines, such as \u003cstrong\u003etumor necrosis factor (TNF)\u003c\/strong\u003e and \u003cstrong\u003eIL6\u003c\/strong\u003e, which can activate inflammatory signaling pathways in hepatocytes—including the JAK-STAT and nuclear factor (NF)-kB pathways—to promote cell proliferation and survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEctopic lymphoid structures:\u003c\/strong\u003e A model of HCC tumorigenesis has been proposed in which leukocytes (white blood cells) that infiltrate the liver organize into ectopic (misplaced) lymphoid-like structures, providing microniches that contain malignant hepatocytic progenitor cells.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdaptive immune cells:\u003c\/strong\u003e Studies of animal models of liver cancer development with non-alcoholic steatohepatitis (NASH) have revealed the role of the adaptive immune system. Factors that activate inflammation, such as NF-kB and the insulin receptor, contribute to carcinogenesis in patients with non-alcoholic fatty liver disease. CD8+ and CD4+ T cells and natural killer cells also promote oncogenesis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIL33-mediated inflammation:\u003c\/strong\u003e The interaction between inflammation and iCCA development has been demonstrated in mice in which biliary epithelial cells that express transgenic AKT and YAP develop only iCCA upon promotion of IL33-mediated biliary tract inflammation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIL6 and iNOS:\u003c\/strong\u003e Other inflammatory mediators that contribute to oncogenesis include IL6 and iNOS. IL6 is highly expressed in human CCAs and promotes cell survival in a STAT3-dependent manner. Interestingly, a gene expression signature associated with IL6-STAT3 signaling has been observed in a subset of human iCCAs.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eImmune Surveillance and the Liver\u003c\/h3\u003e\n\u003cp\u003eNormally, newly transformed (pre-cancerous) cells are eliminated by both the innate and adaptive immune systems in a process called \u003cstrong\u003eimmune surveillance\u003c\/strong\u003e. Cancer cells express antigens (abnormal proteins) that induce adaptive responses mediated by T cells. In the chronically inflamed liver, immune surveillance acts as a critical defense mechanism, preventing the proliferation and expansion of cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eThis understanding raises important questions about treatments that affect the immune system. Notably, some—but not all—recent reports have warned about an \u003cstrong\u003eunexpectedly higher incidence of HCC occurrence and recurrence in patients treated with direct-acting antiviral (DAA) agents\u003c\/strong\u003e, which can cure hepatitis C virus infection. The relationship between DAA treatment, immune function, and liver cancer risk remains an active area of debate and investigation.\u003c\/p\u003e\n\n\u003cp\u003eThe potential impact of curing HCV infection is significant: it has been estimated that \u003cstrong\u003ecuring more than 90% of patients with HCV infection would eliminate 15% of HCC cases in the United States\u003c\/strong\u003e. However, the debate over DAA agents' effects on HCC progression highlights the complexity of the immune-cancer interface.\u003c\/p\u003e\n\n\u003ch2 id=\"molecular-classification\"\u003eMolecular Classification: Profiling Liver Tumors by Their Genes\u003c\/h2\u003e\n\u003cp\u003eRecent advances in genome profiling and next-generation sequencing have revolutionized our understanding of liver cancer. Rather than relying solely on microscopic appearance, researchers can now classify liver cancers based on their \u003cstrong\u003emolecular features\u003c\/strong\u003e—the specific genes that are expressed, mutated, or amplified within tumor cells.\u003c\/p\u003e\n\n\u003ch3\u003eMolecular Classes of Hepatocellular Carcinoma\u003c\/h3\u003e\n\u003cp\u003eBased on gene expression patterns, HCCs have been assigned to several molecular categories:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProliferation-progenitor class:\u003c\/strong\u003e These tumors show gene expression patterns resembling progenitor cells and are associated with more aggressive behavior.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProliferation-transforming growth factor beta (TGF-beta) class:\u003c\/strong\u003e These tumors show activation of the TGF-beta signaling pathway, which can promote cancer growth and spread.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWnt-catenin beta 1 class:\u003c\/strong\u003e These tumors show activation of the Wnt signaling pathway, specifically involving beta-catenin, a key protein that regulates cell division and survival.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eMolecular Classes of Intrahepatic Cholangiocarcinoma\u003c\/h3\u003e\n\u003cp\u003eiCCAs have similarly been assigned to two main molecular categories:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProliferation class:\u003c\/strong\u003e Associated with more aggressive tumor behavior\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInflammation class:\u003c\/strong\u003e Characterized by activation of inflammatory signaling pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhy the Proliferation Subclass Matters\u003c\/h3\u003e\n\u003cp\u003eOverall, \u003cstrong\u003eproliferation subclasses are associated with a more aggressive phenotype and poor patient outcomes\u003c\/strong\u003e. This means that patients whose tumors fall into the proliferation categories generally have a worse prognosis—their cancers tend to grow faster, spread earlier, and respond less well to treatment. Although more specific gene expression signatures have refined our prognostic abilities, the proliferation versus non-proliferation distinction remains a fundamental dividing line in liver cancer biology.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment-targets\"\u003eGenetic Alterations and Potential Treatment Targets\u003c\/h2\u003e\n\u003cp\u003eOne of the most exciting aspects of molecular profiling is the identification of genetic alterations that might be targeted therapeutically. These are the \"Achilles heels\" of cancer—specific vulnerabilities that drugs can exploit:\u003c\/p\u003e\n\n\u003ch3\u003eTargets in Intrahepatic Cholangiocarcinoma (iCCA)\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFGFR2 gene fusions:\u003c\/strong\u003e Rearrangements of the FGFR2 gene that drive cancer growth. Several drugs targeting FGFR2 fusions are in development and clinical trials.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIsocitrate dehydrogenase (IDH) gene mutations:\u003c\/strong\u003e Mutations in these genes are found in \u003cstrong\u003eapproximately 60% of iCCAs\u003c\/strong\u003e. IDH inhibitors, which block the abnormal enzyme produced by these mutated genes, have shown promise in clinical trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eTargets in Hepatocellular Carcinoma (HCC)\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAmplifications at 11q13 and 6p21:\u003c\/strong\u003e These chromosomal regions are amplified (extra copies are present) in \u003cstrong\u003eapproximately 30% of HCCs\u003c\/strong\u003e. These amplifications involve genes that drive cancer cell growth and survival, and they represent potential targets for therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, \u003cstrong\u003efurther studies of these alterations are needed before they can be used as biomarkers in clinical decision making\u003c\/strong\u003e. While these genetic changes offer exciting leads, researchers must validate them in larger patient populations and demonstrate that targeting them improves patient outcomes before they become standard clinical tools.\u003c\/p\u003e\n\n\u003ch2 id=\"prognosis\"\u003eWhat This Means for Patient Prognosis\u003c\/h2\u003e\n\u003cp\u003eThe molecular classification of liver cancer has direct implications for patient prognosis. Understanding which molecular class a patient's tumor falls into can help predict:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDisease aggressiveness:\u003c\/strong\u003e Proliferation subclasses are consistently associated with more aggressive tumor behavior and worse overall survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLikelihood of recurrence:\u003c\/strong\u003e Tumors with stem cell features or proliferation signatures are more likely to recur after treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResponse to therapy:\u003c\/strong\u003e Different molecular classes may respond differently to available treatments, including targeted therapies and immunotherapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAdditionally, the cell of origin appears to influence prognosis. \u003cstrong\u003eLiver cancers with stem cell features—regardless of whether they originated from actual progenitor cells or from de-differentiated hepatocytes—have a more aggressive clinical behavior and worse prognosis\u003c\/strong\u003e than those without stem cell features. This observation has been confirmed across multiple studies and applies to both HCC and iCCA.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: From Laboratory to Bedside\u003c\/h2\u003e\n\u003cp\u003eThe findings reviewed in this article carry several important implications for patients and clinicians:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImproved diagnostic precision:\u003c\/strong\u003e Molecular classification can complement traditional pathology to provide a more accurate picture of a patient's disease. Knowing whether a tumor falls into a proliferation subclass or has specific genetic alterations like FGFR2 fusions or IDH mutations can guide treatment decisions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePersonalized treatment approaches:\u003c\/strong\u003e The identification of targetable genetic alterations—FGFR2 fusions and IDH mutations in iCCA, and amplifications at 11q13 and 6p21 in HCC—paves the way for personalized medicine. Patients whose tumors harbor these alterations may be candidates for targeted therapies that specifically attack cancer cells bearing these changes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrognostic stratification:\u003c\/strong\u003e Molecular features can help identify patients at higher risk for aggressive disease, allowing for more intensive monitoring and earlier intervention.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstanding the role of inflammation:\u003c\/strong\u003e The recognition that 90% of liver tumors develop under conditions of chronic inflammation underscores the importance of preventing and treating the underlying causes of liver inflammation—viral hepatitis, alcohol abuse, and metabolic syndrome.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe DAA controversy:\u003c\/strong\u003e The uncertainty surrounding direct-acting antiviral agents and HCC recurrence highlights the need for careful monitoring of patients treated for HCV infection, even after they achieve a cure.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What Research Cannot Yet Prove\u003c\/h2\u003e\n\u003cp\u003eWhile this review synthesizes a large body of evidence, several important limitations must be acknowledged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnimal model limitations:\u003c\/strong\u003e Much of the evidence about cell of origin comes from mouse models, which may not perfectly recapitulate human disease. Discrepancies between mice and humans make it difficult to draw definitive conclusions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe stem cell controversy:\u003c\/strong\u003e The existence of true stem cells in the adult liver remains heavily debated. It is not clear whether certain cell populations described as \"progenitor cells\" are bona fide stem cells, distinct hepatocyte subpopulations, or something else entirely.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncomplete understanding of when and how cells transform:\u003c\/strong\u003e Researchers do not yet fully understand under what circumstances adult hepatic cells rather than progenitor cells give rise to liver tumors, and vice versa.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTranslation gap:\u003c\/strong\u003e There remains a significant gap between findings from animal model studies (such as cell fate tracing studies) and studies of patients with severe liver injury.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiomarkers not yet validated:\u003c\/strong\u003e The genetic alterations that might be targeted therapeutically (FGFR2 fusions, IDH mutations, 11q13 and 6p21 amplifications) require further study before they can be used as biomarkers in clinical decision making.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnresolved questions about DAA agents:\u003c\/strong\u003e Some—but not all—recent reports have warned about a higher incidence of HCC occurrence and recurrence in patients treated with DAA agents for HCV infection, and this controversy remains unresolved.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Researchers\u003c\/h2\u003e\n\u003cp\u003eBased on the findings in this review, several recommendations emerge for different audiences:\u003c\/p\u003e\n\n\u003ch3\u003eFor Patients\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your risk factors:\u003c\/strong\u003e If you have viral hepatitis (B or C), drink alcohol heavily, have non-alcoholic fatty liver disease, diabetes, or metabolic syndrome, you are at increased risk for liver cancer. Discuss screening and prevention strategies with your healthcare provider.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeek treatment for underlying liver disease:\u003c\/strong\u003e Treating chronic viral hepatitis, managing metabolic syndrome, and avoiding alcohol can reduce your risk of developing liver cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about molecular testing:\u003c\/strong\u003e If you are diagnosed with liver cancer, ask your care team whether molecular profiling of your tumor could help guide treatment decisions. Testing for FGFR2 fusions or IDH mutations in iCCA, or amplifications at 11q13 and 6p21 in HCC, may identify targeted therapy options.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed about clinical trials:\u003c\/strong\u003e Research on targeted therapies for liver cancer is advancing rapidly. Clinical trials may offer access to promising new treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eFor Researchers\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDetermine the dominant reprogramming events\u003c\/strong\u003e involved in tumorigenesis in different species.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExplore which cells are most affected by oncogene mutations\u003c\/strong\u003e associated with HCC, such as those in the TERT promoter or CTNNB1 genes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFill the gap between animal models and human studies\u003c\/strong\u003e to better understand how findings translate across species.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eValidate molecular biomarkers\u003c\/strong\u003e in large patient cohorts before they can be used in routine clinical decision making.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is primary liver cancer and what are its main types?\u003c\/h3\u003e\n\u003cp\u003ePrimary liver cancer is a group of malignant tumors, not a single disease. The most common type is hepatocellular carcinoma, making up about 90% of cases. Other types include intrahepatic cholangiocarcinoma, mixed hepatocellular-cholangiocarcinoma, fibrolamellar carcinoma, and hepatoblastoma. HCC and iCCA are by far the most common, while the others account for less than 1% of cases.\u003c\/p\u003e\n\u003ch3\u003eWhere does liver cancer begin? Which cells give rise to tumors?\u003c\/h3\u003e\n\u003cp\u003eResearch indicates adult hepatocytes are the primary source of most liver cancers. They can transform directly, de-differentiate into primitive cells, or trans-differentiate into bile-duct-like cells that lead to cancer. Progenitor cells may also give rise to some tumors, especially those with stem-cell features. Cholangiocytes appear to cause only intrahepatic cholangiocarcinoma, not hepatocellular carcinoma.\u003c\/p\u003e\n\u003ch3\u003eWhat are the major risk factors for liver cancer?\u003c\/h3\u003e\n\u003cp\u003eFor hepatocellular carcinoma, the main risk factors are chronic hepatitis B or C infection, heavy alcohol use, and non-alcoholic fatty liver disease. Aflatoxin B1 and tobacco use further increase risk. For intrahepatic cholangiocarcinoma, risk factors include primary sclerosing cholangitis, bile duct cysts, hepatolithiasis, and parasitic fluke infection. Chronic hepatitis B and C are also shared risk factors, especially when cirrhosis is present.\u003c\/p\u003e\n\u003ch3\u003eHow are liver cancers classified by molecular features?\u003c\/h3\u003e\n\u003cp\u003eLiver cancers are classified by gene expression patterns. Hepatocellular carcinoma has proliferation-progenitor, proliferation-TGF-beta, and Wnt-catenin beta 1 classes. Intrahepatic cholangiocarcinoma has proliferation and inflammation classes. The proliferation subclass is consistently associated with more aggressive behavior and worse prognosis across both tumor types.\u003c\/p\u003e\n\u003ch3\u003eWhat genetic changes might be targeted with therapy?\u003c\/h3\u003e\n\u003cp\u003eIn intrahepatic cholangiocarcinoma, FGFR2 gene fusions and IDH gene mutations (found in about 60% of cases) are potential targets, with drugs in development or showing promise. In hepatocellular carcinoma, amplifications at 11q13 and 6p21 occur in about 30% of cases. However, these alterations require further study before they can be used as biomarkers in clinical decision making.\u003c\/p\u003e\n\u003ch3\u003eWhat does molecular classification mean for patient prognosis?\u003c\/h3\u003e\n\u003cp\u003eTumors in proliferation subclasses generally have a worse prognosis—they tend to grow faster, spread earlier, and respond less well to treatment. Liver cancers with stem-cell features, regardless of their cell of origin, are more aggressive and have poorer outcomes. Molecular testing may help identify these higher-risk tumors and guide more intensive monitoring or treatment.\u003c\/p\u003e\n\u003ch3\u003eWhat should patients ask their care team about liver cancer?\u003c\/h3\u003e\n\u003cp\u003ePatients should ask whether molecular profiling of their tumor could help guide treatment, including testing for FGFR2 fusions or IDH mutations in iCCA, or amplifications at 11q13 and 6p21 in HCC. They should also discuss treatment of underlying liver disease, such as viral hepatitis or metabolic syndrome, and inquire about clinical trials for targeted therapies.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article:\u003c\/strong\u003e \"Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis\"\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Daniela Sia, Augusto Villanueva, Scott L. Friedman, and Josep M. Llovet, MD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Gastroenterology (Manuscript Number: GASTRO-D-16-01679R1), solicited review article in the Translational section.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Hematology and Medical Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Laboratory, BCLC, Liver Unit, CIBEREHD, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGrant support:\u003c\/strong\u003e The research was supported by the US National Cancer Institute (NCI) (P30CA165979), the European Commission Horizon 2020 (HEP-CAR 667273-2), the Samuel Waxman Cancer Research Foundation, the Grant I+D Program (SAF2013-41027), and the Asociación Española Contra el Cáncer (AECC), among others. Daniela Sia received the Andrea Marie Fuquay Memorial Research Fellowship (Cholangiocarcinoma Foundation), and Augusto Villanueva received the American Association for the Study of Liver Diseases Foundation Alan Hofmann Clinical and Translational Award.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eNote: This patient-friendly article is based on peer-reviewed research published in Gastroenterology. It has been written to make the scientific findings accessible to a broader audience while preserving the accuracy and detail of the original research. It is intended for educational purposes and should not replace professional medical advice.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47457935720604,"sku":null,"price":0.0,"currency_code":"JPY","in_stock":true}],"url":"https:\/\/diagnosticdetectives.tw\/products\/understanding-liver-cancer-where-it-starts-how-its-classified-and-what-this-means-for-patients","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}